Wilson Sonsini Advises RA Capital Management on Corporate, IP Matters Related to Forge Biologics’ $120 Million Series B Financing
- Client Highlights
- Life Sciences
On April 29, 2021, Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced the closing of a $120 million Series B financing. The financing was led by RA Capital Management with participation from Perceptive Advisors and related affiliates, Surveyor Capital (a Citadel company), Octagon Capital, and Marshall Wace. Existing investors Perceptive Xontogeny Venture Fund and Drive Capital also participated. Forge will use the proceeds of this Series B financing to accelerate the expansion of its AAV manufacturing CDMO capabilities with cGMP production capacity, as well as operate its subsidiaries that are advancing novel AAV gene therapy programs. For more information on the Forge Biologics transaction, please see the company's press release.
Wilson Sonsini Goodrich & Rosati advised RA Capital on the transaction. The Wilson Sonsini team includes:
The firm has also advised RA Capital on a number of other recent investments, including Vivace Therapeutics' $30 million Series C financing and Synthego's $100 million Series D financing.